Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline

[1]  B. Hillner,et al.  American society of clinical oncology 2003 update on the role of biophosphonates and bone health issues in women with breast cancer , 2004 .

[2]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Cameron.  Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. , 2003, Breast.

[4]  R. Coleman,et al.  Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. , 2003, Cancer treatment reviews.

[5]  A. Lipton.  Bisphosphonates and metastatic breast carcinoma , 2003, Cancer.

[6]  P. Clézardin.  The antitumor potential of bisphosphonates. , 2002, Seminars in oncology.

[7]  T. Powles,et al.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Metintaş,et al.  Usefulness of bone markers for detection of bone metastases in lung cancer patients. , 2002, Clinical biochemistry.

[9]  G. Hortobagyi,et al.  The evolving role of bisphosphonates. , 2001, Seminars in oncology.

[10]  S. Lauri,et al.  Patients' and nurses' assessment of cancer pain. , 1999, European journal of cancer care.

[11]  G. Hortobagyi,et al.  Bisphosphonates in the Management of Breast Cancer. , 1999, Cancer control : journal of the Moffitt Cancer Center.

[12]  G. Hortobagyi,et al.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[14]  T. Powles,et al.  Clodronate decreases the frequency of skeletal metastases in women with breast cancer. , 1996, Bone.

[15]  J. Hermans,et al.  Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? , 1996, European journal of cancer.

[16]  Farley,et al.  Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. , 1995, Clinical chemistry.

[17]  C. Blomqvist,et al.  Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Powles,et al.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.